An Open-Label Study to Determine the Effect of R1507 Plus Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) With Progressive Disease After Clinical Benefit to Second or Third Line Tarceva Monotherapy.

Trial Profile

An Open-Label Study to Determine the Effect of R1507 Plus Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) With Progressive Disease After Clinical Benefit to Second or Third Line Tarceva Monotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2013

At a glance

  • Drugs Teprotumumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Mar 2013 Planned end date changed from 1 Dec 2010 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top